Dr. Scholnik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
710 Mangum Rd.
Marquette, MI 49855Phone+1 906-869-6543Fax+1 906-249-9562
Education & Training
- University of MichiganFellowship, Hematology and Medical Oncology, 1971 - 1973
- Cleveland Clinic FoundationResidency, Internal Medicine, 1968 - 1971
- Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1968
Certifications & Licensure
- MI State Medical License 1971 - 2025
- OH State Medical License 1969 - 1972
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 198 citationsNational Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.Otis W. Brawley, Llewellyn J. Cornelius, Linda Edwards, Vanessa Northington Gamble, Bettye L. Green
Annals of Internal Medicine. 2008-06-17 - 44 citationsNon-small-cell lung cancer associated with excessive eosinophilia and secretion of interleukin-5 as a paraneoplastic syndrome.Renu Pandit, Aaron Scholnik, Louis Wulfekuhler, Nikolay V. Dimitrov
American Journal of Hematology. 2007-03-01 - 16 citationsNIH consensus development statement on hydroxyurea treatment for sickle cell disease.Otis W. Brawley, Llewellyn J. Cornelius, Linda Edwards, Vanessa Northington Gamble, Bettye L. Green
NIH Consensus and State-of-the-Science Statements. 2008-02-27
Journal Articles
- National Institutes of Health Consensus Development Conference Statement: Hydroxyurea Treatment for Sickle Cell DiseaseOtis W. Brawley, MD, Llewellyn J. Cornelius, PhD, LCSW; Linda R. Edwards, MD, Vanessa Northington Gamble, MD, PhD, Bettye L. Green, RN, Charles Inturrisi, PhD, Andrea ..., Annals of Internal Medicine, 6/17/2008
- Non-small-cell Lung Cancer Associated with Excessive Eosinophilia and Secretion of Interleukin-5 as a Paraneoplastic SyndromePandit, R., Scholnik, A., Wulfekuhler, L., Dimitrov, N., Am J Hematology, 12/7/2006
- To Refer or Not to Refer: Factors that Affect Primary Care Provider Referral of Patients with Cancer to Clinical Treatment TrialsSherwood P.R., Given, B.A., Scholnik, A., Given, C.W., J Cancer Educ, 3/1/2004
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Psychological Characteristics of Patients Who Enter Clinical TrialsScholnik, A.P., Given, C.W., Chapman, R., Gadgeel, S.M., Decker, D., Axelson, J., Proceedings of the American Society of Clinical Oncology, J Clin Onc, 5/31/2003
- Psychological Aspects of Patients Who Enter Clinical TrialsScholnik, A.P., ASCO Annual Meeting, Chicago, IL, 5/31/2003
- Characteristics of Patients Who Enter Clinical TrialsScholnik, A., Given, C.W., Given, B., Patterson, P., Ping, J., Michigan Cancer Consortium Annual Meeting, Ann Arbor, Michigan, 9/13/2002
- Join now to see all
Lectures
- A Common Lexicon for the Pathology Reporting of Breast, Prostate and Colorectal CancersNovi, MI - 9/1/2003
- Primary Care Provider's Attitudes about Cancer Treatment Clinical TrialsAnn Arbor, Michigan - 9/13/2002
- Characteristics of Patients Who Enter Clinical TrialsKarmanos Cancer Center. Detroit, Michigan - 9/11/2002
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: